143 related articles for article (PubMed ID: 37327303)
1. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE.
Hu W; Cao G; Ye S; Xu J; Chen J; Shao G
Medicine (Baltimore); 2023 Jun; 102(24):e34054. PubMed ID: 37327303
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
3. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?
Loffroy R; Lin M; Yenokyan G; Rao PP; Bhagat N; Noordhoek N; Radaelli A; Blijd J; Liapi E; Geschwind JF
Radiology; 2013 Feb; 266(2):636-48. PubMed ID: 23143027
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
[TBL] [Abstract][Full Text] [Related]
5. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography.
Paul SB; Dhamija E; Gamanagatti SR; Sreenivas V; Yadav DP; Jain S; Shalimar ; Acharya SK
Diagn Interv Imaging; 2017 Mar; 98(3):253-260. PubMed ID: 27692674
[TBL] [Abstract][Full Text] [Related]
7. A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis.
Taiji R; Lin YM; Chintalapani G; Lin EY; Huang SY; Mahvash A; Avritscher R; Liu CA; Lee RC; Resende V; Nishiofuku H; Tanaka T; Kichikawa K; Klotz E; Gupta S; Odisio BC
Eur Radiol Exp; 2023 Jan; 7(1):4. PubMed ID: 36717474
[TBL] [Abstract][Full Text] [Related]
8. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography.
Kim SH; Lee WJ; Lim HK; Lim JH
J Comput Assist Tomogr; 2007; 31(2):198-203. PubMed ID: 17414753
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE.
Fronda M; Doriguzzi Breatta A; Gatti M; Calandri M; Maglia C; Bergamasco L; Righi D; Faletti R; Fonio P
Eur Radiol; 2021 Sep; 31(9):6578-6588. PubMed ID: 33738601
[TBL] [Abstract][Full Text] [Related]
10. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
[TBL] [Abstract][Full Text] [Related]
11. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
12. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results.
Ross CJ; Rennert J; Schacherer D; Girlich C; Hoffstetter P; Heiss P; Jung W; Feuerbach S; Zorger N; Jung EM
Clin Hemorheol Microcirc; 2010; 46(2-3):101-15. PubMed ID: 21135486
[TBL] [Abstract][Full Text] [Related]
13. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study of MRI manifestations and pathological changes in hepatocellular carcinoma treated by transcatheter arterial chemoembolization with lipiodol].
Liu R; Wang JH; Zhou KR; Yan FH; Yan ZP; Shen JZ; Tan YS; Cai Y
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):754-8. PubMed ID: 16248948
[TBL] [Abstract][Full Text] [Related]
15. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models.
Vosshenrich J; Zech CJ; Heye T; Boldanova T; Fucile G; Wieland S; Heim MH; Boll DT
Eur Radiol; 2021 Jun; 31(6):4367-4376. PubMed ID: 33274405
[TBL] [Abstract][Full Text] [Related]
16. Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma.
Marquez HP; Karalli A; Haubenreisser H; Mathew RP; Alkadhi H; Brismar TB; Henzler T; Fischer MA
Eur J Radiol; 2017 Jun; 91():160-167. PubMed ID: 28629564
[TBL] [Abstract][Full Text] [Related]
17. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Matsaidonis D
Cardiovasc Intervent Radiol; 2010 Oct; 33(5):1022-7. PubMed ID: 20101403
[TBL] [Abstract][Full Text] [Related]
19. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
20. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
